Nanomedicine

Nanomedicine designates the application of nanotechnology to healthcare through the design and use of nanoscale materials, devices, and systems for diagnosis, prevention, monitoring, and treatment of disease. It encompasses therapeutic and diagnostic approaches exploiting nanoscale properties such as enhanced surface area, tunable interactions with biological systems, and the ability to cross physiological barriers.

The biopharmaceutical industry has accelerated nanomedicine adoption through clinically validated platforms including liposomal chemotherapies, lipid nanoparticle delivery for nucleic acids, and nanoparticle-based imaging agents. Nanomedicine strategies enhance pharmacokinetics by prolonging circulation, reducing clearance, and improving tissue penetration while enabling controlled release and reduced systemic toxicity. Targeted nanomedicine incorporates ligands to bind specific receptors on diseased cells, improving selectivity in oncology and inflammatory diseases. Diagnostic nanomedicine supports earlier detection through sensitive imaging probes and biosensors. Manufacturing and regulatory expectations require robust characterisation of particle size, surface charge, stability, and reproducibility. Safety evaluation addresses potential immunogenicity, biodistribution, and long-term tissue accumulation. As material science advances, nanomedicine continues expanding across oncology, vaccines, gene therapy, and neurology.